Home / CXCL9/MIG / Human CXCL9/MIG Antibody

Human CXCL9/MIG Antibody

Catalog #: MAB392
21 Citations 3 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
MAB392-SP
MAB392-100
MAB392-500
Chemotaxis Induced by CXCL9/MIG and Neutralization by Human CXCL9/MIG Antibody.
2 Images
Product Details
Citations (21)
FAQs
Supplemental Products
Reviews (3)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CXCL9/MIG Antibody Summary

Species Reactivity
Human
Specificity
Detects human CXCL9/MIG in ELISAs and Western blots. In ELISAs, does not cross-react with recombinant mouse (rm) CXCL9, recombinant human CXCL10.
Source
Monoclonal Mouse IgG1 Clone # 49106
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
E. coli-derived recombinant human CXCL9/MIG
Thr23-Thr125
Accession # Q07325
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
Recombinant Human CXCL9/MIG (Catalog # 392-MG)
under non-reducing conditions only
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 
Immunocytochemistry
8-25 µg/mL
See below
Intracellular Staining by Flow Cytometry
2.5 µg/106 cells
THP-1 cells treated with Recombinant Human IFN‑ gamma (Catalog # 285‑IF), fixed with paraformaldehyde, and permeabilized with saponin

Human CXCL9/MIG Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human CXCL9/MIG Biotinylated Antibody (Catalog # BAF392)

Standard: Recombinant Human CXCL9/MIG Protein (Catalog # 392-MG)

Neutralization
Measured by its ability to neutralize CXCL9/MIG-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with mouse CXCR3. The Neutralization Dose (ND50) is typically 0.5-4 µg/mL in the presence of 0.25 µg/mL Recombinant Human CXCL9/MIG.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization Chemotaxis Induced by CXCL9/MIG and Neutralization by Human CXCL9/MIG Antibody. View Larger

Chemotaxis Induced by CXCL9/MIG and Neutralization by Human CXCL9/MIG Antibody. Recombinant Human CXCL9/MIG (Catalog # 392-MG) chemoattracts the BaF3 mouse pro-B cell line transfected with mouse CXCR3 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL9/MIG (0.25 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CXCL9/MIG Monoclonal Antibody (Catalog # MAB392). The ND50 is typically 0.5-4 µg/mL.

Immunocytochemistry View Larger

CXCL9/MIG in THP‑1 Human Cell Line. CXCL9/MIG was detected in immersion fixed THP‑1 human acute monocytic leukemia cell line treated with IFN gamma (positive staining) and THP‑1 human acute monocytic leukemia cell line (untreated; negative staining) using Mouse Anti-Human CXCL9/MIG Monoclonal Antibody (Catalog # MAB392) at 25 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. Staining was performed using our protocol for Fluorescent ICC Staining of Non-adherent Cells.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL9/MIG

CXCL9, a member of the alpha  subfamily of chemokines that lack the ELR domain, was initially identified as a lymphokine-activated gene in mouse macrophages. Human CXCL9 was subsequently cloned using mouse MIG cDNA as a probe. The CXCL9 gene is induced in macrophages and in primary glial cells of the central nervous system specifically in response to IFN-gamma. CXCL9 has been shown to be a chemoattractant for activated T-lymphocytes and TIL but not for neutrophils or monocytes. The human CXCL9 cDNA encodes a 125 amino acid (aa) residue precursor protein with a 22 aa residue signal peptide that is cleaved to yield a 103 aa residue mature protein. CXCL9 has an extended carboxy-terminus containing greater than 50% basic aa residues and is larger than most other chemokines. The carboxy-terminal residues of CXCL9 are prone to proteolytic cleavage resulting in size heterogeneity of natural and recombinant CXCL9. CXCL9 with large carboxy-terminal deletions have been shown to have diminished activity in the calcium flux assay. A chemokine receptor (CXCR3) specific for CXCL9 and IP-10 has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes. The E. coli-expressed CXCL9 preparations produced at R&D Systems have been shown to contain greater than 80% full length CXCL9.

References
  1. Loetscher, M. et al. (1996) J. Exp. Med. 184:963.
  2. Liao, F. et al. (1995) J. Exp. Med. 182:1301.
  3. Vanguri, P. (1995) J. Neuroimmunol. 56:35.
Entrez Gene IDs
4283 (Human); 17329 (Mouse); 246759 (Rat)
Alternate Names
chemokine (C-X-C motif) ligand 9; CMK; crg-10; C-X-C motif chemokine 9; CXCL9; Gamma-interferon-induced monokine; Humig; MIG; MIGSmall-inducible cytokine B9; monokine induced by gamma interferon; SCYB9Monokine induced by interferon-gamma

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Citations for Human CXCL9/MIG Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

21 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Pathogen Evasion of Chemokine Response Through Suppression of CXCL10
    Authors: Alejandro L. Antonia, Kyle D. Gibbs, Esme D. Trahair, Kelly J. Pittman, Amelia T. Martin, Benjamin H. Schott et al.
    Frontiers in Cellular and Infection Microbiology
  2. M1hot tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer
    Authors: Garrido-Martin EM, Mellows TWP, Clarke J et al.
    J Immunother Cancer
  3. CXCR3/Ligands Are Significantly Involved in the Tumorigenesis of Basal Cell Carcinomas
    Authors: Blanche Ka Ki Lo, Mei Yu, David Zloty, Bryce Cowan, Jerry Shapiro, Kevin John McElwee
    The American Journal of Pathology
  4. Chemokine positioning determines mutually exclusive roles for their receptors in extravasation of pathogenic human T cells
    Authors: F Parween, SP Singh, HH Zhang, N Kathuria, FA Otaizo-Car, A Shamsaddin, PJ Gardina, S Ganesan, J Kabat, HA Lorenzi, TG Myers, JM Farber
    bioRxiv : the preprint server for biology, 2023-02-13;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  5. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy
    Authors: M Pascual-Ga, E Bonfill-Te, E Planas-Rig, C Rubio-Pere, R Iurlaro, A Arias, I Cuartas, A Sala-Hojma, L Escudero, F Martínez-R, I Huber-Ruan, P Nuciforo, L Pedrosa, C Marques, I Braña, E Garralda, M Vieito, M Squatrito, E Pineda, F Graus, C Espejo, J Sahuquillo, J Tabernero, J Seoane
    Nat Commun, 2019-06-11;10(1):2416.
    Species: Human
    Sample Types: Organoid
    Applications: Neutralization
  6. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
    Br J Cancer, 2016-08-04;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  7. Intracellular coexpression of CXC- and CC- chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation.
    Authors: Pinto S, Martinez-Romero A, O'Connor J, Gil-Benso R, San-Miguel T, Terradez L, Monteagudo C, Callaghan R
    BMC Cancer, 2014-02-22;14(0):118.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  8. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN-lambda) in cutaneous lupus erythematosus.
    Authors: Zahn S, Rehkamper C, Kummerer BM, Ferring-Schmidt S, Bieber T, Tuting T, Wenzel J
    J. Invest. Dermatol., 2010-08-19;131(1):133-40.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  9. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver.
    Authors: Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LS, Adams DH
    J. Immunol., 2010-02-17;184(6):2886-98.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  10. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome.
    Authors: Yoon KC, Park CS, You IC, Choi HJ, Lee KH, Im SK, Park HY, Pflugfelder SC
    Invest. Ophthalmol. Vis. Sci., 2009-10-22;51(2):643-50.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  11. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention.
    Authors: Franciszkiewicz K, Le Floc'h A, Jalil A, Vigant F, Robert T, Vergnon I, Mackiewicz A, Benihoud K, Validire P, Chouaib S, Combadiere C, Mami-Chouaib F
    Cancer Res., 2009-07-28;69(15):6249-55.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  12. CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis.
    Authors: Busuttil A, Weigt SS, Keane MP, Xue YY, Palchevskiy V, Burdick MD, Huang C, Zisman DA, Fishbein M, Lynch JP, Strieter RM, Elashoff RM, Belperio JA
    Eur. Respir. J., 2009-04-22;34(3):676-86.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  13. Upregulation of human cytomegalovirus by HIV type 1 in human lymphoid tissue ex vivo.
    Authors: Biancotto A, Iglehart SJ, Lisco A, Vanpouille C, Grivel JC, Lurain NS, Reichelderfer PS, Margolis LB
    AIDS Res. Hum. Retroviruses, 2008-03-01;24(3):453-62.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Luminex Development
  14. Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients.
    Authors: Winter D, Moser J, Kriehuber E, Wiesner C, Knobler R, Trautinger F, Bombosi P, Stingl G, Petzelbauer P, Rot A, Maurer D
    J. Immunol., 2007-09-15;179(6):4272-82.
    Species: Human
    Sample Types: Serum, Whole Tissue
    Applications: IHC-Fr, Immunodepletion
  15. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.
    Authors: Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, Debernardo R, Garate K, Rodriguez B, Margolis LB, Lederman MM
    Blood, 2007-02-08;109(10):4272-9.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Luminex Development
  16. HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1.
    Authors: Grivel JC, Elliott J, Lisco A, Biancotto A, Condack C, Shattock RJ, McGowan I, Margolis L, Anton P
    AIDS, 2007;21(10):1263-72.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Luminex Development
  17. CXCR 3 activation promotes lymphocyte transendothelial migration across human hepatic endothelium under fluid flow.
    Authors: Curbishley SM, Eksteen B, Gladue RP, Lalor P, Adams DH
    Am. J. Pathol., 2005-09-01;167(3):887-99.
    Species: Human
    Sample Types: Tissue Homogenates, Whole Tissue
    Applications: IHC, Western Blot
  18. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma.
    Authors: Suyama T, Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ichikawa T, Ueda T, Nikaido T, Ito H, Ishikura H
    Cancer, 2005-01-15;103(2):258-67.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  19. Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands.
    Authors: Kohrgruber N, Groger M, Meraner P, Kriehuber E, Petzelbauer P, Brandt S, Stingl G, Rot A, Maurer D
    J. Immunol., 2004-12-01;173(11):6592-602.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  20. Ectopic expression of the chemokine CXCL17 in colon cancer cells
    Authors: Ohlsson L, Hammarstrom ML, Lindmark G et al.
    Br. J. Cancer
  21. Herpes Simplex Virus Type 2 Infection-Induced Expression of CXCR3 Ligands Promotes CD4+ T Cell Migration and Is Regulated by the Viral Immediate-Early Protein ICP4
    Authors: Mudan Zhang, Xu Deng, Xinmeng Guan, Lanlan Geng, Ming Fu, Binman Zhang et al.
    Frontiers in Immunology

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human CXCL9/MIG Antibody

Average Rating: 5 (Based on 3 Reviews)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human CXCL9/MIG Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human CXCL9/MIG Antibody
By Katie Myers on 11/14/2022
Application: ELISA Sample Tested: Serum Species: Primate

Worked as a capture antibody in our non-human primate ELISA

ELISA Human CXCL9/MIG Antibody MAB392
Human CXCL9/MIG Antibody
By Anonymous on 09/04/2021
Application: Immunocytochemistry/Immunofluorescence Sample Tested: macrophages Species: Human

CXCL9 antibody showed positive macrophages in hepatitis liver tissue.

Immunocytochemistry/Immunofluorescence Human CXCL9/MIG Antibody MAB392
Human CXCL9/MIG Antibody
By Anonymous on 12/06/2017
Application: ELISA Sample Tested: Serum and Plasma Species: Human

This antibody was used as a capture in a sandwich ELISA for MIG. The detection antibody was BAM392. The standard was 392-MG-010. Sensitivity was around 5 pg/ml.

ELISA Human CXCL9/MIG Antibody MAB392